Jonjones325 Friday, 04/05/19 06:18:25 PM Re: None Post # of 231002 Thanks Bourbon for the great reporting. Even though I did not attend this year, my brother did. Here are the notes he took. Bourbon has already mentioned some of these. Hopefully this offers some more perspective. Someone asked if there would be another trial after the phase 2B/3. Missling stated that this one is our phase 3 not a pre-phase 3. I’m taking that to assume that no other trial would be needed afterwards. There will be an upcoming “large” publication about our Phase 2a Alz trial. Pretty exciting! 2019 is our "execution year". We have dosed the 1st Rett patient and know who all 15 are and "have them on speed dial". I’m guessing this means they will all be dosed shortly. Have not analyzed patients after the 148 weeks. They will wait and do a 208 week analysis. Reiterated that the 148 week results included patients that "did not get sufficient drugs". To maximize shareholder value will wait till Rett and PDD read out before making a deal. BP is willing to pay for results. 1M worth of drugs on hand enough for all ongoing trials and the beginning of commercialization. He joked that they had enough to "treat all of Manhattan". Good dialog with ACTC and "expecting some movement" on that especially in light of the Biogen failure. Biogen MS MTA is done. Will soon present on microbiota and its link to CNS brain issues. My brother made a comment about autophagy which made him giddy. Read into this as you choose.